Alkermes Investor Relations Material
Latest events
Q2 2025
Alkermes
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Alkermes plc
Access all reports
Alkermes plc is a biopharmaceutical company engaged in the development, manufacturing, and commercialization of innovative medicines. The company focuses on therapies for central nervous system disorders, including schizophrenia, bipolar disorder, and addiction, as well as treatments for other chronic diseases. Alkermes serves the healthcare sector by advancing solutions that address unmet medical needs. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.
Key slides for Alkermes plc
Q4 2024
Alkermes plc
Q2 2025
Alkermes plc
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
ALKS
Country
🇺🇸 United States